Familial adenomatous polyposis (FAP) patients treated with Aptosyn experienced a clinically significant reduction in precancerous colon polyp formation after six months of therapy. Over 18 months, patients showed an overall 75% reduction in polyps, highlighting the compound's potential as a treatment for FAP.
Researchers at CWRU's Frances Payne Bolton School of Nursing are studying the effects of a new intervention program on cardiac patients' exercise habits. The CHANGE program uses small-group counseling and behavior modification techniques to help patients maintain long-term, positive exercise habits.
Researchers from the University of Florida College of Medicine have developed a new therapy using bacteriophages to treat Vibrio vulnificus infections. Most mice injected with both the bacterium and a deadly bacteriophage survived what would normally be a fatal infection, demonstrating the effectiveness of this approach.
A study found that 40% of cancer patients use unconventional medical therapies and do not report this information unless specifically asked by their physicians. These therapies, such as mega-doses of vitamins and herbal supplements, can potentially interfere with radiation treatment.
Introgen presents Phase I trial results on RPR/INGN 201, showing safety and expression in ovarian cancer, lung carcinoma, and glioblastoma patients. The therapy has demonstrated significant potential in treating these life-threatening conditions.
Researchers train embryonic stem cells into oligodendrocytes, which can rewrap nerve axons and remyelinate damaged spinal cords. The study demonstrates a potential approach to restoring neurological function in patients with conditions such as multiple sclerosis and spinal cord injury.
Researchers found that estrogen use reduced cognitive decline in women with e2 and e3 ApoE alleles, but not in those with e4 variants. Estrogen also showed protective effects on carotid wall thickening and atherosclerosis.
Dr. Achilles A. Demetriou will present information on the bioartificial liver (BAL), an external device that cleanses blood plasma through synthetic and biologic materials, during Digestive Disease Week. The BAL has completed a Phase I clinical trial at Cedars-Sinai and is now in a large multi-center study.
A new minimally invasive radio-guided parathyroidectomy (MIRP) technique allows surgeons to remove parathyroid glands with fewer complications, reducing surgery time from several hours to just 30 minutes. This outpatient procedure also enables patients to go home within a few hours, compared to days of hospitalization.
Abarelix depot-M successfully suppresses testosterone levels, achieving suppression by day 8 and maintaining it from day 29 through day 85. The studies validated PRAECIS' core technology and demonstrate a potentially new treatment option for prostate cancer.
A study by Johns Hopkins Medicine found that 31% of recent popular press articles on epilepsy contained gross mistakes, including inaccurate science and exaggerated treatment claims. The print media often reflect and shape views about epilepsy, but also perpetuate misconceptions that can shame patients.
The study confirms that M-Vax increases the survival rate of patients with advanced Stage III melanoma, even after disease recurrence. Patients who developed an immune response against their melanoma had a far better outcome, with a five-year survival rate of 65%.
Matthew Warman, an assistant professor of genetics and pediatrics at CWRU, has been selected as a Hughes assistant investigator by the Howard Hughes Medical Institute. He will receive funding for his research on rare and common human genetic diseases, aiming to improve human health.